Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells
Jutatip Panaampon, Ryusho Kariya, Seiji Okada
Topics & Concepts
Antibody-dependent cell-mediated cytotoxicityCancer researchCD16BiologyImmunologyMonoclonal antibodyAntibodyCD3AntigenCD8Immune Cell Function and InteractionLymphoma Diagnosis and TreatmentT-cell and B-cell Immunology